Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Baden – page 8

865 clinical trials in Baden, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Baden at a glance
865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

865 trials in Baden

Open in trial search

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RO7589655
  • Sponsor:F. Hoffmann-La Roche AG

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen - Cilag International

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Myopia

Recruiting

Safety and Efficacy of Sodium Phenylbutyrate Eye Drops in Children with Myopia

Investigational
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Sodium Phenylbutyrate
  • Sponsor:Laboratoires Thea

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Belatacept Dose Reduction Safety in Kidney Transplant Recipients with a Well-Matched Donor

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Belatacept
  • Sponsor:Medical University Of Vienna

Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Deciphera Pharmaceuticals Inc.

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Baden

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer evaluating personalized treatment approaches using targeted therapies.

  • Adjuvant therapy optimization
  • Personalized treatment strategies
  • Novel drug combinations

Studies aim to improve survival rates through dynamic marker-adjusted therapeutic approaches.

02 Triple-Negative Breast Cancer

Research examining neoadjuvant treatment options for patients with early-stage triple-negative breast cancer, comparing innovative therapeutic combinations.

  • Treatment response assessment
  • Immunotherapy combinations
  • Survival outcome evaluation

Focus on improving treatment efficacy in low-risk recurrence patients.

03 Ovarian Cancer Studies

Advanced research on HRD-positive high-grade ovarian cancer, investigating optimized treatment durations and maintenance therapy approaches.

  • Chemotherapy optimization
  • Maintenance therapy evaluation
  • Recurrence prevention strategies

Emphasis on improving outcomes for patients with no residual tumor after debulking surgery.

04 Leukemia Research

Groundbreaking studies in chronic lymphocytic leukemia (CLL) examining novel drug combinations for high-risk patients.

  • Targeted therapy combinations
  • High-risk patient treatment
  • Disease progression prevention

Investigation of innovative triple-combination therapies for improved patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.